You're reading the free version. Trader adds the live tape and alerts.
Start tracking
ELVN Sale Disclosure
Collins Helen Louise · SEC Form 4 · Filed Sep 21, 2026
Sale
Calculated transaction value
$145.89K
Collins Helen Louise Chief Medical Officer
ELVN
Enliven Therapeutics
ELVN
Transaction date
Sep 17, 2026
Public filing date
Sep 21, 2026
Filing lag
Filed 4 days later
ELVN daily price context
Close on/before transaction
$50.24
Sep 17, 2026
First close after public filing
$48.19
Sep 22, 2026
30-day return after filing
-13.22%
Through Oct 21, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 2,916 shares @ $50.03
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001701247-26-000013
Filing cohort
Transactions in this filing
Showing 5 of 5
Trades
5
Issuers
1
Estimated value
$264.15K
Buys / sales
0 / 3
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Enliven Therapeutics, Inc. ELVN | Sale | Sep 17, 2026 | $93.51K |
| Enliven Therapeutics, Inc. ELVN | Exercise | Sep 17, 2026 | $12.4K |
| Enliven Therapeutics, Inc. ELVN Current | Sale | Sep 17, 2026 | $145.89K |
| Enliven Therapeutics, Inc. ELVN | Sale | Sep 17, 2026 | $12.36K |
| Enliven Therapeutics, Inc. ELVN | Exercise | Sep 17, 2026 | $0 |